Evidence map›Paper›PMID 36459955›Full record

ArticleRespiratory medicine2023

Risk of hospitalization in a sample of COVID-19 patients with and without chronic obstructive pulmonary disease.

Laura C Myers, Richard Murray, Bonnie Donato, Vincent X Liu, Patricia Kipnis, Asif Shaikh, Jessica Franchino-Elder

Abstract read
In one paragraph

Article in Respiratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease.Annals of the American Thoracic Society · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura C MyersThe Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Electronic address: Laura.c.myers@kp.org.
Richard MurraySpire Health, San Francisco, CA, USA.
Bonnie DonatoHealth Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Vincent X LiuThe Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Patricia KipnisThe Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Asif ShaikhClinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Jessica Franchino-ElderHealth Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivePatients with chronic obstructive pulmonary disease (COPD) may have worse coronavirus disease-2019 (COVID-19)-related outcomes. We compared COVID-19 hospitalization risk in patients with and without COPD.

methodsThis retrospective cohort study included patients ≥40 years, SARS-CoV-2 positive, and with Kaiser Permanente Northern California membership ≥1 year before COVID-19 diagnosis (electronic health records and claims data). COVID-19-related hospitalization risk was assessed by sequentially adjusted logistic regression models and stratified by disease severity. Secondary outcome was death/hospice referral after COVID-19. RESULTS AND DISCUSSION: Of 19,558 COVID-19 patients, 697 (3.6%) had COPD. Compared with patients without COPD, COPD patients were older (median age: 69 vs 53 years); had higher Elixhauser Comorbidity Index (5 vs 0) and more median baseline outpatient (8 vs 4), emergency department (2 vs 1), and inpatient (2 vs 1) encounters. Unadjusted analyses showed increased odds of hospitalization with COPD (odds ratio [OR]: 3.93; 95% confidence interval [CI]: 3.40-4.60). After full risk adjustment, there were no differences in odds of hospitalization (OR: 1.14, 95% CI: 0.93-1.40) or death/hospice referral (OR: 0.96, 95% CI: 0.72-1.27) between patients with and without COPD. Primary/secondary outcomes did not differ by COPD severity, except for higher odds of hospitalization in COPD patients requiring supplemental oxygen versus those without COPD (OR: 1.84, 95% CI: 1.02-3.33).

conclusionsExcept for hospitalization among patients using supplemental oxygen, no differences in odds of hospitalization or death/hospice referral were observed in the COVID-19 patient sample depending on whether they had COPD.

Indexed as

COVID-19Pulmonary Disease, Chronic ObstructiveAgedComorbidityCOVID-19 TestingHospitalizationHumansOxygenRetrospective StudiesSARS-CoV-2OxygenCOPDCOVID-19Healthcare resource usePneumonia

Identifiers

PMID36459955
PMCPMC9700393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.